GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (ASX:ATH) » Definitions » Cyclically Adjusted PB Ratio

Alterity Therapeutics (ASX:ATH) Cyclically Adjusted PB Ratio : (As of May. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Alterity Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alterity Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alterity Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Cyclically Adjusted PB Ratio Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.39 0.60 0.31 0.17

Alterity Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.17 - - -

Competitive Comparison of Alterity Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alterity Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Cyclically Adjusted PB Ratio falls into.



Alterity Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alterity Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alterity Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/126.3989*126.3989
=0.000

Current CPI (Dec. 2023) = 126.3989.

Alterity Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
200806 0.049 85.071 0.073
200812 0.030 85.814 0.044
200906 0.018 86.278 0.026
200912 0.033 87.578 0.048
201006 0.022 88.971 0.031
201012 0.011 89.993 0.015
201106 0.025 92.129 0.034
201112 0.019 92.686 0.026
201206 0.019 93.244 0.026
201212 0.028 94.730 0.037
201306 0.037 95.473 0.049
201312 0.048 97.330 0.062
201406 0.077 98.352 0.099
201412 0.075 99.002 0.096
201506 0.073 99.838 0.092
201509 0.000 100.302 0.000
201512 0.068 100.673 0.085
201606 0.059 100.859 0.074
201612 0.052 102.159 0.064
201706 0.044 102.809 0.054
201712 0.038 104.110 0.046
201806 0.030 104.945 0.036
201812 0.020 105.967 0.024
201906 0.019 106.617 0.023
201909 0.000 107.174 0.000
201912 0.013 107.917 0.015
202006 0.007 106.246 0.008
202012 0.017 108.846 0.020
202103 0.000 109.496 0.000
202106 0.015 110.332 0.017
202109 0.000 111.168 0.000
202112 0.017 112.654 0.019
202203 0.000 115.069 0.000
202206 0.015 117.112 0.016
202209 0.000 119.248 0.000
202212 0.012 121.477 0.012
202303 0.000 123.148 0.000
202306 0.009 124.170 0.009
202309 0.000 125.656 0.000
202312 0.000 126.399 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alterity Therapeutics  (ASX:ATH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alterity Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (ASX:ATH) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.